Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II Trial;Studio randomizzato multicentrico in doppio cieco dello stent Endeavor a rilascio di zotarolimus e rivestito di fosforilcolina per il trattamento de lesioni su arterie coronariche native. Risultati clinici e angiografici dello Studio ENDEAVOR II

Minerva Cardioangiologica

Volumn 55, Issue 1, 2007, Pages 1-18

  Fajadet, J ^a   Wijns, W ^b,k   Laarman, G J ^c   Kuck, K H ^d   Ormiston, J ^e   Munzel T ^f   Popma, J J ^g   Fitzgerald, P J ^h   Bonan, R ⁱ   Kuntz, R E ^j  

^a CLINIQUE PASTEUR   (France)

^b CARDIOVASCULAR CENTER   (Belgium)

^c OLV Gasthuis   (Netherlands)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e Mercy Hospital   (New Zealand)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ MEDTRONIC INC   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k OLV HOSPITAL   (Belgium)

more..

Author keywords

Coronary disease; Restenosis; Revascularization; Stents

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; MAMMALIAN TARGET OF RAPAMYCIN; POLYMER; RAPAMYCIN; RAPAMYCIN DERIVATIVE; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DEVICE; DOUBLE BLIND PROCEDURE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME;

AGED; AUSTRALIA; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY STENOSIS; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; EUROPE; FEMALE; HUMANS; ISRAEL; MALE; MIDDLE AGED; NEW ZEALAND; PACIFIC ISLANDS; PHOSPHORYLCHOLINE; PROSPECTIVE STUDIES; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33947580364     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA 2000;284:1828-36.
2. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: a hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
3. Nordmann AJ, Hengstler P, Leimenstoll BM, Harr T, Young J, Bucher HC. Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: a meta-analysis of randomized controlled trials. Eur Heart J 2004;25:69-80.
4. Scheen AJ, Warzee F, Legrand VM. Drug-eluting stents: meta-analysis in diabetic patients. Eur Heart J 2004;25:2167-8.
5. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schomig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875-80.
6. Mercado N, Boersma E, Wijns W, Gersh BJ, Morillo CA, de Valk V et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001;38:645-52.
7. Nikol S, Huehns TY, Hofling B. Molecular biology and post-angioplasty restenosis. Atherosclerosis 1996;123:17-31.
8. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C et al. for the SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23.
9. Stone GW, Ellis ST, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT et al. for the TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-31.
10. Babapulle MN, Joseph L, Belisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drugeluting stents. Lancet 2004;364:583-91.
11. Guagliumi G, Virmani R, Musumeci G, Motta T, Valsecchi O, Bonaldi G et al. Drug-eluting versus bare metal coronary stents: long-term human pathology: findings from different coronary arteries in the same patient. Ital Heart J 2003;4:713-20.
12. Finn AV, Kolodgie FD, Harnek J, Guerrero LJ, Acampado E, Tefera K et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
13. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109: 701-5.
14. Degetekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A et al. Long-term follow-up of incomplete stent apposition in patients who received the sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation 2003;108:2747-50.
15. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-21.
16. Food and Drug Administration. FDA advises physicians of adverse events associated with Cordis Cypher coronary stents. In: US Food and Drug Administration Public Health Web Notification; 2003:T03-T71. http://www.fda.gov/cdrh/safety/cypher3.html.
17. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
18. Meredith IT, Ormiston JA, Whitbourn R, Kay IP, Miller D, Bonan R et al. First-in-human study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I trial. EuroIntervention 2005;1: 157-64.
19. Sketch MH Jr, Ball M, Rutherford B, Popma JJ, Russell C, Kereiakes DJ, for the Driver Investigators. Evaluation of the Medtronic (Driver) cobaltchromium alloy coronary stent system. Am J Cardiol 2005;95:8-12.
20. Whelan DM, van der Giessen WJ, Krabbendam SC, van Vliet EA, Verdouw PD, Serruys PW et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 2000;83:338-45.
21. Boland JL, Corbeij HA, Van Der Giessen WJ, Seabra-Gomes R, Suryapranata H, Wijns W et al. Multicenter evaluation of the phosphorylcholine-coated BiodivYsio stent in short de novo coronary arteries: the SOPHOS study. Int J Cardiovasc Intervent 2000;3:215-25.
22. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression; new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9.
23. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5.
24. Lewis AL, Tolhrst LA, Stratford PW. Analysis of phosphorylcholinebased polymer coating on a coronary stent pre- and post-implantation. Biomaterials 2002;23:1697-706.
25. Mehran R, Mintz GS, Satler LF, Pichard AD, Kent KM, Bucher TA et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. Circulation 1997;96:2183-9.
26. van der Zwet PM, Reiber JH. A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results. J Am Coll Cardiol 1994;24:216-24.
27. Ruygrok PN, Melkert R, Morel MA, Ormiston JA, Bar FW, Fernandez- Aviles F et al. Does angiography six months after coronary intervention influence management and outcome? Benestent II Investigators. J Am Coll Cardiol 1999;34:1507-11.
28. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-5.
29. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111:3435-42.
30. Lemos PA, Mercado N, van Domburg RT, Kuntz RE, O'Neill WW, Serruys PW. Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 2004;110:3199-205.
31. Windecker S, Simon R, Lins M, Klauss V, Eberli FR, Roffi M et al. Randomized comparison of a titanium-nitric-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005;111:2617-22.
32. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation study. Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-42.
33. Ribichini F, Tomai F, Ferrero V, Versaci F, Boccuzzi G, Proietti I et al. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease: the IMPRESS-2/MVD study. EuroIntervention 2005;1:173-80.
34. Kipshidze N, Dangas G, Tsapenko M, Moses J, Leon MB, Kutryk M et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004;44: 733-9.
35. Edelman ER, Rogers C. Stent-versus-stent equivalency trials: are some stents more equal than others? Circulation 1999;100:896-8.
36. Kastrati A, Schömig A, Elezi S, Schuhlen H, Dirschinger J, Hadamitzky M et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol 1997;30:1428-36.
37. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation 1994;90:1239-51.
38. Mauri L, O'Malley AJ, Cutlip DE, Ho KK, Popma JJ, Chauhan MS et al. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 2004;93: 1340-6, A5.